ReviewChemistry (Weinheim an der Bergstrasse, Germany)2025
Recent Cutting-Edge Technologies for the Delivery of Peptide Nucleic Acid.
Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Modulating G-quadruplexes for therapeutic intervention: Structural diversity, stability, and emerging nucleic-acid-based strategies.Molecular therapy. Nucleic acids · 2026Review
- Multiple Charged Purine (MCP) PNA as a Simple Mode for Cellular Uptake.ACS polymers Au · 2026Article
- Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy.International journal of molecular sciences · 2026Review
- Facile Preparation of PNA-Peptide Conjugates with a Polar Maleimido-Thioether Linkage.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Evaluation of Peptide Nucleic Acid Encapsulation in Ferritin Nanocages for Gene Silencing Applications.Biomacromolecules · 2025Article
- 7-Methylguanine With a Cyclopentane Backbone: A Bright Combination for a FIT-PNA RNA Sensor.British journal of biomedical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Peptide nucleic acids (PNAs) have garnered significant attention due to their enhanced chemical, physical, and binding properties in comparison to natural nucleic acids. This prompted their application in antigene/antisense approach, assigning them a pivotal role in gene editing and, more recently, showing their potential as "bilingual" molecules being able "to speak" both nucleic acid and protein language. However, to expand the applications of PNAs in therapy, the challenge of effectively delivering PNAs to cells needs to be addressed. Among several delivery approaches employed so far, the nanotechnology-based ones showed great potential. In this review, we provide an overview of the latest in the field (2019 to present), beginning from peptide-based delivery systems, as well as cutting-edge approaches involving nanoparticles, liposomes, and calixarene, showing how they have inspired the development of smarter delivery approaches to boost PNAs applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.